Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497875 | 0.84 | ALDH1A1 (0.53) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL6232266 | 0.76 | MGAM (0.38) | ALDH1A1TDP1TRPA1SLC1A1 | |
| SCHEMBL8860533 | 0.76 | CES2 (0.43) | ALDH1A1TDP1 | |
| SCHEMBL10923900 | 0.75 | SLC1A1 (0.33) | SLC1A1 | |
| SCHEMBL597670 | 0.73 | ALDH1A1 (0.46) | ALDH1A1LMNASLC15A2TDP1 | |
| SCHEMBL28060459 | 0.72 | ALDH1A1 (1.00) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL10001 | 0.72 | — | — | |
| SCHEMBL57742 | 0.72 | ALDH1A1 (0.59) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL888729 | 0.72 | ALDH1A1 (0.59) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL328134 | 0.71 | USP2 (0.43) | SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | NEOPHARM, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2006029081-A2 | NUCLEOSIDE-LIPID CONJUGATES, THEIR METHOD OF PREPARATION AND USES THEREOF | NEOPHARM, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | ALDH1A1 4029/4885LMNA 1174/4885SLC15A2 2311/4885 |
| US-20100323000-A1 | METHOD AND PROCESS FOR PREPARING CARDIOLIPIN | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 4113/4885LMNA 360/4885SLC15A2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.